Q1 Earnings Forecast for GH Research Issued By HC Wainwright

GH Research PLC (NASDAQ:GHRS) – Research analysts at HC Wainwright lifted their Q1 2025 earnings per share estimates for GH Research in a report released on Tuesday, March 4th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.19) per share for the quarter, up from their previous forecast of ($0.22). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for GH Research’s Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.82) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.92) EPS and FY2028 earnings at ($0.46) EPS.

GHRS has been the topic of several other reports. Canaccord Genuity Group decreased their target price on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Cantor Fitzgerald initiated coverage on GH Research in a report on Thursday, February 13th. They set an “overweight” rating and a $14.00 price objective on the stock. Royal Bank of Canada assumed coverage on GH Research in a research note on Friday. They issued an “outperform” rating and a $31.00 price objective on the stock. Finally, Stifel Nicolaus raised their target price on GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $30.67.

GH Research Price Performance

Shares of GH Research stock opened at $10.50 on Friday. GH Research has a 52-week low of $6.00 and a 52-week high of $20.50. The firm has a market capitalization of $546.29 million, a PE ratio of -13.29 and a beta of 0.94. The company’s fifty day moving average price is $10.80 and its two-hundred day moving average price is $9.18.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06.

Institutional Trading of GH Research

Large investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. raised its stake in shares of GH Research by 1.3% in the third quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock valued at $44,734,000 after acquiring an additional 85,000 shares during the last quarter. Geode Capital Management LLC increased its holdings in GH Research by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock valued at $508,000 after purchasing an additional 3,092 shares in the last quarter. Diadema Partners LP bought a new position in GH Research in the 4th quarter valued at $711,000. Lynx1 Capital Management LP boosted its stake in GH Research by 15.8% in the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after purchasing an additional 663,100 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in shares of GH Research by 26.8% during the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock worth $286,000 after purchasing an additional 8,641 shares during the last quarter. 56.90% of the stock is owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).